Telomir Pharmaceuticals (TELO) Competitors $1.16 -0.01 (-0.85%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.17 +0.01 (+0.86%) As of 07/11/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. BIOA, IKT, BDTX, NLTX, ALEC, TIL, GALT, LXEO, KYTX, and RAPTShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include BioAge Labs (BIOA), Inhibikase Therapeutics (IKT), Black Diamond Therapeutics (BDTX), Neoleukin Therapeutics (NLTX), Alector (ALEC), Instil Bio (TIL), Galectin Therapeutics (GALT), Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), and Rapt Therapeutics (RAPT). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors BioAge Labs Inhibikase Therapeutics Black Diamond Therapeutics Neoleukin Therapeutics Alector Instil Bio Galectin Therapeutics Lexeo Therapeutics Kyverna Therapeutics Rapt Therapeutics BioAge Labs (NASDAQ:BIOA) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation. Does the media favor BIOA or TELO? In the previous week, BioAge Labs and BioAge Labs both had 1 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat BioAge Labs' score of 0.93 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment BioAge Labs Positive Telomir Pharmaceuticals Very Positive Which has preferable valuation and earnings, BIOA or TELO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/ATelomir PharmaceuticalsN/AN/A-$16.53M-$0.42-2.76 Do analysts rate BIOA or TELO? Telomir Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 1,193.10%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is BIOA or TELO more profitable? BioAge Labs' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioAge LabsN/A N/A N/A Telomir Pharmaceuticals N/A -2,009.40%-1,009.72% SummaryTelomir Pharmaceuticals beats BioAge Labs on 6 of the 8 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.82M$2.45B$5.60B$9.11BDividend YieldN/A1.79%5.24%4.02%P/E Ratio-2.769.4227.9620.25Price / SalesN/A729.02430.5799.61Price / CashN/A165.3637.4658.16Price / Book58.004.608.045.49Net Income-$16.53M$31.26M$3.18B$250.27M7 Day Performance-1.69%4.80%3.63%4.75%1 Month Performance-42.00%5.42%4.04%7.64%1 Year Performance-71.91%-4.36%29.56%16.34% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals3.5753 of 5 stars$1.16-0.9%$15.00+1,193.1%-71.1%$34.82MN/A-2.761Positive NewsBIOABioAge LabsN/A$4.13flatN/AN/A$148.06MN/A0.00N/AIKTInhibikase Therapeutics1.2067 of 5 stars$1.95flat$6.50+233.3%+36.0%$144.97M$260K-0.736BDTXBlack Diamond Therapeutics2.769 of 5 stars$2.48flat$12.80+416.1%-46.8%$141.02MN/A41.3390News CoveragePositive NewsNLTXNeoleukin TherapeuticsN/A$14.95-7.5%N/A-49.1%$140.50MN/A-4.8190High Trading VolumeALECAlector3.9984 of 5 stars$1.42+1.4%$4.00+181.7%-70.2%$139.99M$100.56M0.00270News CoveragePositive NewsTILInstil Bio3.3715 of 5 stars$21.93+5.3%$119.00+442.6%+152.5%$136.62MN/A0.00410GALTGalectin Therapeutics2.1026 of 5 stars$2.22+5.2%$6.00+170.3%+6.4%$133.54MN/A-3.089News CoverageLXEOLexeo Therapeutics2.3479 of 5 stars$4.22+5.0%$16.60+293.4%-74.4%$133.45M$650K0.0058KYTXKyverna Therapeutics2.5011 of 5 stars$2.77-9.8%$18.50+567.9%-58.1%$132.68M$7.03M0.0096News CoverageRAPTRapt Therapeutics4.4474 of 5 stars$7.33-8.4%$24.00+227.4%-69.6%$132.29M$1.53M0.0080Positive NewsAnalyst Forecast Related Companies and Tools Related Companies BioAge Labs Alternatives Inhibikase Therapeutics Alternatives Black Diamond Therapeutics Alternatives Neoleukin Therapeutics Alternatives Alector Alternatives Instil Bio Alternatives Galectin Therapeutics Alternatives Lexeo Therapeutics Alternatives Kyverna Therapeutics Alternatives Rapt Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
